CMPS surges after reporting $466 million in cash, a 211% annual increase, extending runway into 2028 ahead of its first drug launch.
Compass Pathways (CMPS) shares reached a two-year high Wednesday after the company reported $466 million in cash and equivalents as of March 31, up 211% year-over-year. The cash position is expected to fund operations through 2028, bolstering confidence ahead of its first drug launch.
The biotech firm’s cash reserves compare to $149.8 million in the same quarter last year. The surge follows a recent executive order by President Donald Trump tied to psychedelic drugs, which previously lifted CMPS shares in April.
No immediate market reaction details were provided, but the stock’s upward momentum reflects investor optimism about the company’s financial stability and pipeline.